2023
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists
Madanat Y, Zeidan A. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists. Clinics In Laboratory Medicine 2023, 43: 685-698. PMID: 37865511, DOI: 10.1016/j.cll.2023.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow biopsy reportsAvailable treatment optionsBest therapeutic approachClinical presentationPathologic findingsRisk stratificationTherapeutic optionsTreatment optionsBiopsy reportsDisease entityTherapeutic approachesTreatment considerationsAccurate diagnosisGenetic abnormalitiesDiagnosisDisease subclassificationPatientsNeoplasmsHematopathologistsOptionsPrognosticationAbnormalitiesCliniciansSubclassification
2017
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars In Cancer Biology 2017, 52: 103-109. PMID: 29183778, PMCID: PMC5970946, DOI: 10.1016/j.semcancer.2017.11.019.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaCell lung carcinomaLung cancerWorld Health OrganizationLung carcinomaSignificant prognostic impactLung cancer patientsRecent large-scale genomic studiesSmall biopsy specimensDriver gene mutationsPrognostic impactCancer patientsBiopsy specimensTargeted therapyOncologic practiceAccurate subclassificationIHC biomarkersImmunohistochemical markersPatient careAccurate diagnosisImmunotherapyTherapyCancerSubclassificationCritical roleBiomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects
Osmani L, Li QK. Biomarkers in the accurate subclassification of non-small-cell lung carcinoma for targeted therapy: issues and prospects. Biomarkers In Medicine 2017, 11: 405-407. PMID: 28621614, DOI: 10.2217/bmm-2017-0059.Peer-Reviewed Original Research
2013
Cirrhosis Regression and Subclassification
Bedossa P, Garcia-Tsao G, Jain D. Cirrhosis Regression and Subclassification. Surgical Pathology Clinics 2013, 6: 295-309. PMID: 26838976, DOI: 10.1016/j.path.2013.03.006.Peer-Reviewed Original ResearchFibrosis areaSeptal widthChronic liver diseaseNodule sizeCirrhosis regressionPortal hypertensionUnderlying diseaseHemodynamic consequencesLiver diseaseLiver fibrosisSuccessful treatmentVascular remodelingDisease severityCirrhosisEnd pointFibrosisDiseaseProgressionClassification systemHypertensionDecompensationSubclassification
2007
Celiac Lymph Nodes and Esophageal Cancer
Rice T, Boffa D. Celiac Lymph Nodes and Esophageal Cancer. 2007, 271-278. DOI: 10.1007/978-1-84628-474-8_33.Peer-Reviewed Original ResearchCeliac lymph nodesEsophageal cancerLymph nodesThoracic esophageal cancerAmerican Joint CommitteeGestational trophoblastic tumorsDistant metastatic sitesDistant metastasisMetastatic sitesStaging recommendationsTrophoblastic tumorJoint CommitteeDisease sitesCancerProstateTestisEsophagusMetastasisMelanomaTumorsRetinoblastomaSubclassification
1978
Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma
Strauchen J, Young R, Devita V, Anderson T, Fantone J, Berard C. Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma. New England Journal Of Medicine 1978, 299: 1382-1387. PMID: 362206, DOI: 10.1056/nejm197812212992503.Peer-Reviewed Original ResearchConceptsComplete response rateDiffuse histiocytic lymphomaHistopathological subclassificationExcellent prognosisIntermediate prognosisBetter prognosisPoor prognosisHistiocytic lymphomaMorphologic subclassificationHistopathological categoriesHeterogeneous diseaseClinical relevancePrognosisResponse rateMorphologic featuresLymphomaChemotherapyPatientsTumorsSubclassificationSurvivalDifferencesDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply